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Abstract
ICAM-l Transmembrane Signaling:
Involvement of TAXREB107 in ICAM-l-mediated Signal Transduction
Brian Lee 
May 2001
The role of membrane ICAM-l in intercellular adhesion, through interaction with 
the leukocyte (32 integrin receptors LFA-1 and Mac-1, is well established. However, 
until recently, ICAM-l was widely regarded as being simply an “anchor” molecule, 
promoting, for example, firm adhesion of lymphocytes to vascular endothelial cells. The 
demonstration that ICAM-l is connected to the actin-based cytoskeleton through 
interactions with subcortical actin-binding proteins, such as a-actinin, enhanced this 
concept. However, ICAM-l has been increasingly shown to have signaling properties of 
its own. Engagement of ICAM-l extracellularly, either through its natural counter­
receptors, LFA-l/Mac-1, or through antibody mediated clustering, can produce 
numerous changes within the cell. Recent evidence now confirms that ICAM-l 
crosslinking induces multiple activation responses including: 1 ) phosphorylation of 
several cytoplasmic proteins, including cortactin, cdc2  kinase and lyn kinase; (2 ) 
activation o f the Erk 1/2 MAP kinases; and (3) induction of various functional cellular 
responses such as oxidative burst from mononuclear leukocytes, neutrophil activation,
i
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and rho activation in endothelial cells. Although we know o f several downstream targets 
o f ICAM-l engagement, very little is known about upstream events, i.e., the most 
proximal components of the signaling cascade involving direct protein interactions with 
the ICAM-l cytodomain, or through indirect interactions in a multimeric unit.
The specific aim o f this project is to study the proximal aspects of ICAM-l 
signaling. The hypothesis is that ICAM-l-mediated signal transduction requires 
interactions between currently unidentified intracellular proteins and the cytoplasmic 
domain o f ICAM-l. In these studies, TAXREB107, a recently discovered protein, was 
specifically associated with the ICAM-l cytodomain in GST-pulldown experiments 
using human endothelial cell extracts. This association was biochemically confirmed by 
co-immunoprecipitations o f recombinantly expressed TAXREB107 and the ICAM-l 
cytodomain, as well as endogenous TAXREB107 and ICAM-l. Recombinant 
TAXREB107, expressed in a wide spectrum of mammalian cell types, greatly augmented 
the ERK 1/2 MAPK activation induced by activating antibody or natural ligand 
(fibrinogen) engagement o f ICAM-l. This amplifying effect was abolished by co­
expression of the ICAM-l, but not VCAM-1 cytodomain. Furthermore, 
immunofluorescence studies demonstrated that TAXREB 107, which possesses DNA- 
binding capability, is predominantly located in the cytoplasm in non-activated CHO or 
human endothelial cells, and rapidly translocates to the nucleus upon ICAM-l 
engagement. These data demonstrate an interaction between the ICAM-l cytoplasmic 
tail and TAXREB 107, and support that this interaction can lead to a productive 
amplification of proximal ICAM-l-mediated signaling. This may consequently stimulate
ii
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gene expression of TAXREB-responsive genes or promote a spectrum o f ERK-mediated 
cellular responses, also including gene activation.
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Chapter 1 Introduction
1.1 ICAM-l — Classification and Early Studies
Adhesion molecules play an indispensable role in the development and 
homeostasis of most higher organisms. By serving to mediate cell-cell interactions, they 
play a role in such diverse functions as immunity, hematopoiesis, and embryonic 
development. Because o f their ubiquitous expression and involvement in so many 
biological processes, this class of molecules has been extensively studied. This discussion 
will focus on the role o f adhesion molecules in immunity and disease looking in particular 
at the specific activities of intercellular adhesion molecule-1 within this framework. In 
terms of immunity, three major groups of adhesion molecules exist (van de Stolpe et al., 
1996):
A) Immunoglobulin-like cell adhesion molecules — Single chain transmembrane 
molecules containing multiple in-series domains resembling those found in 
immunoglobulin heavy and light chains. Examples include intercellular adhesion molecule- 
1 (ICAM-l), vascular cell adhesion molecule-1 (VCAM-1), and platelet/endothelial cell 
adhesion molecule-1 (PECAM-1).
B) Integrins -- Heterodimeric transmembrane proteins consisting of an a  chain and 
a P chain, often capable of functioning as receptors for one or more Ig-like adhesion 
molecules. Integrin families are classified based on their particular P chain. For example, 
members of the p2 integrin subfamily include LFA-1 (CD 11 a/CD 18), and Mac-1
1
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(CD1 lb/CD 18). Ia  their resting configuration, integrins usually have very low affinity for 
their ligand, e.g., LFA-1/ICAM-l interactions have a o f only 10' 5 or 10' 6 M in the 
inactive state (Lollo et al., 1993). Once LFA-1 or Mac-1 are activated, affinity for 
ICAM-l increases dramatically (Dustin et al., 1989). The P2 integrin-ICAM-1 
interaction is also dependent upon divalent cations (Marlin et al., 1987).
C) Selectins — Monomeric transmembrane molecules related to the sugar-binding 
lectins. They are involved in the early stages of leukocyte localization, by causing 
leukocytes in the bloodstream to “slow roll” along the vascular endothelium adjacent to 
sites of inflammation. These molecules bind to either mucin-like glycoproteins 
(GlyCAM-1 and CD34) or sialylated forms of oligosaccharides (sialylated Lewis X). 
Members of this family include L-selectin, P-selectin and E-selectin.
In early studies of leukocyte-leukocyte and leukocyte-endothelial interactions, 
lymphocyte function-associated molecules (LFA-1, -2, -3) were discovered to be essential 
mediators (Sanchez-Madrid et al., 1982). Monoclonal antibodies developed against the 
LFA’s, and LFA-1 in particular, were shown to be effective in blocking adhesion 
between almost all known combinations of leukocyte-leukocyte and leukocyte-target cell 
interactions (Sanchez-Madrid et al., 1982). The hypothesis at that time was that the cell­
cell binding was caused by homotypic interaction between LFA molecules on both cells. 
However, this was quickly disproven in studies using LAD1 cells which were deficient in 
p2 integrins such as LFA-1 and Mac-1 (Rothlein et al., 1986). These studies 
demonstrated that it is possible for phorbol ester stimulated LFA-1+ cells to bind LFA-17 
Mac-1' cells, indicating that there was an unidentified molecule serving as an LFA-1
2
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ligand. By laboriously screening a large panel o f monoclonal antibodies (mAb’s) that did 
not bind to LFA-1, yet inhibited LFA-1 mediated adhesion, Rothlein et al. were able to 
eventually narrow down to one monoclonal antibody, RR1 (Rothlein et al., 1986). 
Building on this information, the cloning of ICAM-l was not far behind (Simmons et al., 
1988).
Since LFA-1 binds to all known ICAM’s (ICAM-l, -2, -3), it is evident in 
retrospect why RR1 was not able to block all LFA-1-mediated interactions. Within four 
years after ICAM -l was cloned, ICAM-2 and ICAM-3 had also been cloned (Staunton et 
al., 1989; de Fougerolles et al., 1994). At this stage, there was no known cell line whose 
LFA-1 dependent adhesion could not be blocked by a cocktail o f anti-ICAM-1, -2, and -3 
monoclonal antibodies.
1.2 Gene and Protein Structure
ICAM-l is a 505 amino acid protein composed o f five Ig-iike domains in its 
extracellular portion (453 mostly hydrophilic residues) , a transmembrane region (24 
residues), and finally, a  cytoplasmic domain (28 residues) (van de Stolpe et al., 1996).
The gene structure is relatively simple with seven total exons (separated by six introns), 
one for each o f the Ig-like domains, one for the transmembrane domain, and the last exon 
for the cytoplasmic tail. Comparisons between various mammalian ICAM-l sequences 
have been made, showing a relatively nonconserved gene across species. There appears to 
be only 55-65% homology between human and other mammalian ICAM-l sequences (Siu
<■»
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et al., 1989; Kita et al., 1992; Manning et al., 1995). This is surprising considering that 
the LFA-l/ICAM-1 interaction is very specific in its binding. Only the first Ig-like 
domain (the domain furthest away from the membrane) on ICAM-l can bind to LFA-1, 
even though the other domains are similar in structure and sterically available (Mac-1, 
another (32 integrin which has similar structure to LFA-1, binds to the more inner Ig-like 
domain 3). Interestingly, ICAM-l gene knockout is nonlethal in mice, although several 
immunological deficits are apparent (Sligh et al., 1993). Since ICAM-2 and -3 are also 
known to be ligands for LFA-1 (Simmons, 1995), perhaps evolutionary development of 
ICAM-l need not maintain strict conservation across generations. In fact, ICAM-2 
appears quite different from ICAM-l and -3 in that it only has two Ig-like domains. 
Besides this, the observation that the ICAM-2 gene maps to chromosome 17q23-25 
whereas ICAM-l and -3 closely map on chromosome 19pl3.2-13.3 seems to indicate 
that the divergence between the two sets o f genes occurred relatively early on (Simmons,
1995).
Glycosylation patterns vary widely among cell types so that the molecular weight 
of human ICAM-l is in the range of 80-114 kDa (van de Stolpe et al., 1996). ICAM-l is 
heavily N-glycosylated, such that approximately half o f its mass is generated by 
oligosaccharides. The projected size of a fully deglycosylated ICAM-l is approximately 
56 kDa. Why such heavy glycosylations exist remains unclear, but available evidence 
suggests that it may serve a  regulatory purpose. When the N-linked oligosaccharides in 
Ig-like domain 3 of ICAM-l were removed, Mac-1 was found to have much higher 
affinity (Diamond et al., 1991). ICAM-3, which is very closely related to ICAM-l, also
4
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shows a similar effect at Ig-like domain 3 (Simmons, 1995). Presence of glycans in 
domain 1 o f ICAM-l do not appear to affect binding to LFA-1 or Mac-1.
Each Ig-like domain forms a (3-sheet structure, which is stabilized by highly 
conserved cysteine residues in all but the fourth Ig-like domain, which has its own set of 
conserved residues, presumably necessary to stabilize its p-sheet structure in the absence 
of disulfide bridges (Staunton et al., 1990). ICAM-l is presumed to form a linear chain of 
the five Ig-like domains based on two separate lines o f work (Giranda et al., 1990;
Staunton et al., 1990).
An interesting peculiarity about the extracellular domain of the ICAM molecules 
is that they do not possess the RGD domains usually seen in integrin ligands (Staunton et 
al., 1990). This is consistent with the lack of Ca2+ requirement in ICAM/P2 integrin 
binding, although Mg2+ and/or Mn2+ play important roles. In addition to interactions 
with p2 integrins, ICAM-l has been reported to interact with a number of other 
molecules, including fibrinogen, hyaluronan, and CD43 (Rosenstein et al., 1991; Languino 
etal., 1993; McCourt et al., 1994).
The cytoplasmic tails of the ICAM’s are the most nonhomologous regions among 
the different ICAM molecules, which has led to speculation that this may provide a basis 
for outside-in signaling specificity (Simmons, 1995). All three ICAM’s have short 
cytoplasmic tails without any apparent enzymatically active domains. However, several 
potential phosphorylation sites exist within each. While potential signaling functions 
have been shown for ICAM-l and ICAM-3, none has yet been shown for ICAM-2.
5
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1.3 ICAM-l signaling
There have been multiple demonstrations o f intracellular events occurring upon 
membrane ICAM-l engagement by activating antibodies. Among the earliest reports, 
Carpen et al. provided biochemical evidence (in a nonfunctional setting) of a direct 
association between a-actinin and the ICAM-l cytodomain (CD) by demonstrating 
binding of purified a-actinin to a synthetic ICAM-l cytodomain peptide, as well as to 
immunoaffinity purified ICAM-l (Carpen et al., 1992). Later, brain microvessel 
endothelial cells that were stimulated with either anti-ICAM-1 antibodies or syngeneic 
encephalitogenic T cells were shown to undergo p60 src tyrosine phosphorylation, which 
led to phosphorylation o f a src substrate, cortactin (Durieu-Trautmann et al., 1994). Since 
a previous report demonstrated that p60src-mediated tyrosine phosphorylation led to 
disassembly of adherens junctions (Volberg et al., 1991; Tsukita et al., 1992), the link 
between ICAM-l and cytoskeletal elements was further strengthened. Recently, 
Adamson et al. also showed that antibody-mediated ICAM-l crosslinking resulted in a 
reorganization o f the endothelial actin cytoskeleton to form stress fibers and activation of 
the small guanosine triphosphate (GTP)-binding protein Rho, an effect blockable by 
addition of C3 transferase, a specific inhibitor of Rho (Adamson et al., 1999). Occludin, 
an integral membrane protein localizing at tight junctions and linked to the actin 
cytoskeleton, is phosphorylated after ICAM-l crosslinking (Hirase et al., 2000). This 
event correlates with an increase in tight junction permeability in endothelial cell 
monolayers. This, and the occludin phosphorylation, are blocked by addition of a Rho
6
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kinase inhibitor, Y-27632, or adenoviral transduction o f the endothelial cells with a 
dominant-negative Rho A mutant
Other pathways not immediately linked with the cytoskeleton have also been 
implicated in ICAM-l-mediated signaling. ICAM-3 can stimulate a number of T cell 
functions such as activation and secretion of IL-2 by inducing phosphorylation of Fyn, 
Lck, and CD45 (Juan et al., 1994). Since ICAM-l and -3 are similar in overall structure, 
the same phosphorylation targets were screened after ICAM-l stimulation.
Paradoxically, a transient inhibition of kinase activity in a T cell tumor line was observed, 
via tyrosine phosphorylation of cdc2 , a posttranscriptional modification shown to inhibit 
this cell cycle progression regulating protein. (Chirathawom et al., 1995).
In a murine B cell tumor line, antibody-mediated ICAM-l crosslinking results in 
class II major histocompatibility complex upregulation as well as tyrosine 
phosphorylation o f  the src family kinase, lyn (Holland et al., 1997). ICAM-l stimulation 
also results in Raf-1 and Erk-1 activation in this B ceil line indicating that this MAP 
kinase pathway is activated as a result o f ICAM-l engagement. The ICAM-l-mediated 
ERK activation has also been observed in human vascular endothelial cells (HUVEC) and 
further shown to be involved in IL- 8  (interleukin-8 ) and RANTES (regulated upon 
activation, normal T-cell expressed and secreted) production (Sano et al., 1998). IL- 8  
belongs to a group o f molecules known as C-X-C chemokines, which are known to serve 
as chemoattractants and activators of neutrophils in vivo (Strieter et al., 1989). RANTES 
belongs to the C-C chemokine group, attracting T cells and eosinophils in vitro (Schall et
7
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al., 1990; Rot et al., 1992). Thus, the ICAM-l engagement by leukocyte (32 integrins (or 
other ligands) may amplify cell recruitment through triggering chemokine production.
The effect o f  ICAM-l engagement on oxidative burst in neutrophils and 
mononuclear phagocytes has been investigated. In CD14+ peripheral blood mononuclear 
cells (PBMCs), crosslinking membrane ICAM-l with anti-ICAM-1 monoclonal 
antibodies plus F(ab ’ ) 2  fragments o f goat anti-mouse IgG, in the presence o f suboptimal 
levels of the bacterial peptide FMLP, results in oxidative burst (Rothlein et al., 1994). In 
human neutrophils, ICAM-l crosslinking causes an increase in oxidative burst, an increase 
in Mac-1 expression , and a decrease in L-selectin expression (Vuorte et al., 1999).
Gene activation by ICAM-l crosslinking has also been examined. ICAM-l 
crosslinking triggers a rise in cytosolic free calcium, followed by a 2-3 fold increase in 
ICAM-l mRNA levels (peaking at 1-3 hr.), and maximal protein expression between 18- 
48 hr (Clayton et al., 1998). Similar protein expression patterns have been observed for 
VCAM-1 after ICAM -l crosslinking. Very recently, differential display after ICAM-l 
stimulation was performed. At 2 hrs, induced and downregulated genes were clearly 
demonstrated, but the actual identities of the genes within each group were not identified. 
(Kohlmeier et al., 2 0 0 0 ).
As with several other cell types, ICAM-l engagement in rat astrocytes causes Erk 
activation by phosphorylation (Ettiene-Manneville et al., 1999). In addition, in these 
same cells, increased levels o f both intracellular cAMP and the phosphorylated form of 
the transcription factor, cAMP response element-binding protein (CREB), are seen after
8
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ICAM-l stimulation. These events are partially dependent on protein kinase C, which 
can act as an indirect activator o f cAMP/PKA and Erk pathways.
Most o f the previous ICAM-l signaling studies have used activating antibodies to 
promote membrane molecular clustering. There have, however, been a small number of 
studies done with soluble fibrinogen as a stimulating ligand. As previously mentioned, 
fibrinogen has been shown to bind to ICAM-l, as well as to other cell adhesion molecules 
such as Mac-1 and CR4 (CD11 c/CD 18), 0 ^ 3 , and anb P3 (platelet gpIIb/IIIa) (Wright et 
al., 1988; Altieri et al., 1990; Rosales et al., 1995). Recently, the fibrinogen binding site 
on ICAM-l has been examined in greater detail and found to be on Ig-like domain 1 
(Duperray et al., 1997). This site is apparently distinct from the LFA-1 or Mac-1 binding 
sites. Fibrinogen has been found to increase relaxation in saphenous vein rings in lower 
concentrations (0-2 |iM), an effect which can be blocked by addition of anti-ICAM-1 
antibodies (Hicks et al., 1996). Interestingly, inhibiting nitric oxide synthesis with L- 
NAME or addition of the nitric oxide trap, hemoglobin, caused only a small change in the 
fibrinogen-mediated relaxation response, while inhibition of prostacyclins, another family 
of vasodilators synthesized by the endothelium produced similar results. Only a 
combination of L-NAME and indomethacin caused an appreciable change in the 
fibrinogen-mediated relaxation response.
Fibrinogen stimulation of human saphenous vein endothelial cells induces the 
secretion of MCP-1 (Harley et al., 1999). This effect was mimicked by activating anti- 
ICAM-1 antibodies. Fibrinogen also induces proliferation in Raji B cells, an effect 
blockable with peptides corresponding to an extracellular portion of ICAM-l (Giranda et
9
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al., 1990). This was attributed to fibrinogen-induced Erk-1 activation, inhibitable with the 
same extracellular ICAM-l peptide.
1.4 ICAM-l Cytodomain Interactions
While the work presented above describes several potentially important cellular 
responses to ICAM-l-mediated signaling, there remains little known about the most 
proximal events in these activation responses. That is, for these responses to occur, the 
cytoplasmic tail o f ICAM-l must be playing either a direct or indirect role. Attempts to 
define ICAM-l cytodomain-interacting proteins have generally yielded a consistent 
pattern, in that many of the identified molecules are related to the cytoskeleton. Since 
ICAM -l’s major function is to serve as an anchoring molecule between two cells, it is not 
surprising to find cytoskeletal adaptor proteins binding to the ICAM-l cytodomain.
ICAM-l cytodomain associates with a-actinin in a region close to the 
transmembrane domain where a cluster of basic residues resides (Carpen et al., 1992). 
Positive charge alone is not sufficient for this interaction, as several other positively 
charged peptides, when tested, failed to bind to a-actinin. p-tubulin and glyceraldehyde- 
3-phosphate dehydrogenase also interact with the ICAM-l cytodomain (Federici et al.,
1996). The P-tubulin association raises the possibility that ICAM-l interacts with 
microtubules in addition to actin filaments, consistent with the general theme of ICAM-l 
association with the cytoskeleton. The potential biologic meaning of the glyceraldehyde- 
3-phosphate dehydrogenase interaction is not clear. Giyceraldehyde-3-phosphate
10
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dehydrogenase functions in one o f the intermediate steps o f the glycolysis pathway, 
converting glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate. This is the first redox 
reaction o f glycolysis and requires NAD+. Glyceraldehyde-3-phosphate dehydrogenase 
uses its C-terminal domain to interact with ICAM-l cytodomain, which is also the site of 
its NAD+ binding site. Thus, NAD+ could potentially compete with ICAM-l 
cytodomain for binding to glyceraldehyde-3-phosphate dehydrogenase. It is therefore 
possible that ICAM-l engagement alters cellular metabolism, but this has not been 
investigated.
Ezrin, a member o f the ERM (ezrin/radixin/moesin) family of proteins, which are 
involved in linking the actin-containing cytoskeleton to the plasma membrane, also binds 
ICAM-l (Heiska et al., 1998). This interaction is direct, as determined by plasmon 
resonance, and depends on the presence o f phosphatidylinositol 4,5-bisphosphate 
(PtdIns(4,5)P2). This is interesting because ezrin and other ERM proteins are 
downstream components o f the rho signaling pathway, which was previously shown to 
be involved in the ICAM-l-mediated formation o f actin stress fibers. Since rho regulates 
phosphatidylinositol 4-phosphate 5-kinase, which synthesizes PtdIns(4,5)P2 , rho could 
control ezrin-ICAM-1 interactions as well (Chong et al., 1994).
1 1
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1.5 ICAM-l as a Pathological Basis of Disease
ICAM-l has been implicated in a vast array of human diseases ranging from the 
common cold to cancer. Some examples of these ICAM-l-mediated diseases are as 
follows:
1.5.1 Infectious diseases:
Rhinoviruses have been described as the single most important etiologic agent of 
the common cold (Bella et al., 2000). The mechanism of their entry into human cells has 
been pieced together using a variety of ICAM-l/HRV fragments for crystallographic 
studies as well as electron micrography. The small icosahedral virus must first bind 
ICAM-l (most serotypes of the human rhino virus (HRV) use ICAM-l as the surface 
receptor for entry into human nasal epithelial cells), which causes a conformational change 
in the virus that allows for uncoating of the protein capsid and injection of the RNA 
genome into the cytoplasm (Casasnovas, 2000). Rhinovirus attachment is confined to the 
BC, CD, DE, and FG loops of the amino-terminal Ig-like domain 1 (the end furthest from 
the membrane). Since domain 1 differs considerably between human ICAM-l and -2, 
there is no HRV interaction with ICAM-2 (Bella et al., 1999).
Malaria caused by the most virulent of Plasmodia, P. falciparum, has a very 
unique property. Erythrocytes infected with P. falciparum gain the ability to bind 
vascular endothelial cells in an ICAM-l-mediated fashion at a site distinct from the LFA-
12
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1 binding site, probably contributing to the clinical symptomatology of the disease as a 
result (Berendt et al., 1989; Ockenhouse et al., 1992).
1.5.2 Cancer:
The relationship between ICAM-l and melanomas has been examined extensively. 
At first, it was thought that ICAM-l could serve as a marker of progression to 
malignancy, since ICAM-l expression increases as melanocytes transform into 
melanomas (Johnson et al., 1989). This is paradoxical because T-cell/target cell 
interactions are, in part, ICAM-l mediated, potentially increasing the likelihood of T cell 
recognition. However, melanomas actually shed ICAM-l, generating a soluble form that 
can competitively inhibit leukocyte adhesion. In fact, soluble ICAM-l and anti-CD 1 la 
monoclonal antibody equally inhibit the leukocyte-melanoma interactions (Becker et al., 
1995). It has been proposed that, through leukocyte adhesion, melanoma cells can spread 
hematogenously, eventually adhering to the endothelium and diapedesing (Simmons.
1995).
ICAM-l levels have been studied in both acute and chronic forms of lymphocytic 
leukemia. ICAM-l expression in acute B-lymphocytic leukemia (ALL) is undetectable 
(Moller et al., 1993), while chronic lymphocytic leukemia (CLL) lymph nodes sections 
are strongly ICAM-1+ (Csanaky, 1994). Therapy for CLL and hairy cell leukemia often 
includes interferon-a which induces ICAM-l and is thought to provide clinical benefit by 
increasing the targeting of these cancers by cytotoxic T cells (Marotta et al., 1993).
13
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Among other B-lymphoid cancers, higher ICAM-l expression levels appear to 
correlate with relatively benign disease, whereas lower ICAM-l levels appear to portend 
a less favorable prognosis (van de Stolpe et al., 1996). This is certainly the case for both 
Hodgkin’s and non-Hodgkin’s lymphomas. T-lymphoid cancers are more difficult to 
characterize relative to ICAM-l expression since no trends have been identified to date. 
However, a recent report described the protective effects o f ICAM-l knockout on the 
dissemination o f malignant T lymphoma cells (Aoudjit et al., 1998).
1.5.3 Autoimmune Diseases:
Several autoimmune disorders have been studied in terms of their ICAM-l 
profiles, including rheumatoid arthritis, vasculitis, type-1 diabetes, sarcoidosis, lupus 
nephritis, autoimmune glomerulonephritis, autoimmune thyroid disease, and autoimmune 
hepatitis (van de Stolpe et al., 1996). ICAM-l knockout mouse models have been useful 
in this arena. In these models, absence o f ICAM-l produces a dramatic increase in mouse 
survival with a normally rapidly fatal form of systemic autoimmune disease, characterized 
by glomerulonephritis and vasculitis, similar to severe cases of systemic lupus 
erythematosus (Bullard et al., 1997).
1.5.4 Atherosclerosis:
Since atherosclerosis is an inflammatory disease with chronic and superimposed 
acute features, the role o f ICAM-l in atherogenesis has been investigated. Monocytes 
and T cells adhere to the arterial endothelial surface and migrate into the subendothelial
14
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space in animals fed an atherogenic diet, the same pattern seen in histological studies of 
human arterial plaque sections (Watanabe et al., 1998). In hypercholesterolemic rats, 
ICAM-l upregulation is observed primarily in lesion-prone areas o f aorta during the early 
stages of atherogenesis. Increased endothelial ICAM-l expression was also thought to 
increase fibrinogen deposition due to fibrinogen’s known capacity for binding ICAM-l on 
its first Ig-like domain (Duperray et al., 1997) leading to plaque formation (Languino et 
al., 1993). In a murine venous bypass graft model, the normally observed neointimal 
hyperplastic response is reduced by 30-50% in ICAM-l KO mice (Zou et al., 2000).
1.5.5 Septic Shock:
Not surprisingly, ICAM -l also plays a role in septic shock, due to 
iipopolysaccharide’s strong induction of various cytokines, e.g., IL-1 and TNFa, as well 
as ICAM-l itself. These inflammatory cytokines induce the augmented expression of 
ICAM-l and thereby increase neutrophil (through (52 integrins) adherence and fibrinogen 
binding. Increased neutrophil extravasation causes vascular hyperpermeability, edema, 
and septic shock (Xu et al., 1994), while fibrinogen has been implicated as a causative 
factor in disseminated intravascular coagulation (DIC) (van de Stolpe et al., 1996).
1.5.6 Neurological Disease:
An increasing number o f studies are being performed on neural systems with 
respect to ICAM-l expression. Besides studies of ICAM-l intracellular signaling in 
astrocytes and glial cells mentioned previously, studies are being conducted on diseased
15
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neural tissue as well. In one study, the differential expression of ICAM-l in the 13- 
amyloid containing plaques o f Alzheimer brains demonstrated a striking amount of 
ICAM-l immunohistochemical staining in granular and Purkinje cell plaques vs. those in 
the molecular layer (Verbeek et al., 1996).
1.5.7 Transplantation:
In acute allograft rejection, recipient T cells recognize transplanted, allogeneic 
tissue by way o f T cell receptor-MHC (plus peptide) interactions. This primary 
allorecognition is insufficent to generate the full amplitude of alloactivation responses. 
Adhesion molecules and costimulatory receptor-ligand interactions are also required. 
ICAM-l can serve both adhesion strengthening and costimulatory ligand functions. 
Through the engagement o f its counter-receptor LFA-1, several mechanisms are triggered 
which amplify T cell activation (Wang et al., 1998). In the course of events preceding the 
actual placement of the graft in the recipient, ischemia followed by reperfusion of the 
grafted tissue can induce ICAM-l expression on graft endothelium. When given as 
intraperitoneal injections four weeks after small intestine transplantation in mice, anti- 
ICAM-1 and anti-LFA-L antibodies prolong allograft survival. (Kato et al., 1996). Six 
weeks after cessation of antibody treatments, these mice have normal mucosa without 
signs of rejection. This not only has implications for the parenchymal tissue within the 
graft, but also for its vasculature, since transplant-associated arteriosclerosis remains an 
obstacle to long-term graft survival. In a mouse allogeneic carotid artery graft model, 
neointima formation is reduced by 52%, 33%, and 38%, in ICAM-l, MHC II, or MHC I
16
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plus MHC H KO mice, respectively, (Shi et al., 1999). ICAM-l antibodies also reduce 
postsinusoidal WBC adherence following ischemia and reperfusion, in a rat liver 
transplantation model (Meyer et al., 1998).
1.6 TAXREB107
Human T cell leukemia virus (HTLV) type 1 is the etiological agent involved in 
two human diseases: Adult T cell leukemia (ATL) and HTLV-1-associated myelopathy / 
tropical spastic paraparesis (HAM/TSP) (Yoshida et al., 1995). Although the exact 
mechanisms o f disease causation by HTLV-1 have not been entirely worked out, the 
pathological basis o f these diseases is partially dependent on a  viral protein named tax for 
its transactivating properties. HTLV-1 actually has two important gene regulatory 
proteins, tax and rex (Inoue et al., 1987). Tax was first shown to activate transcription of 
viral genes upon viral entry into the cell by binding to an enhancer in the LTR (long 
terminal repeat) region o f the viral genome containing an imperfect triplicate of a 21-bp 
element (Shimotohno et al., 1986; Brady et al., 1987; Rosen et al., 1987). O f interest, 
each p21 element o f the triplicate in the tax-responsive enhancer can be further subdivided 
into three highly conserved domains (A, B, and C) of approximately 4-5 bps each 
(Fujisawa et al., 1989). Tax absolutely requires domain B to bind, but the roles of A and 
C remain in question (Fujisawa et al., 1989). Rex, on the other hand, controls the 
processing of viral RNA.
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Both proteins are vital to the normal replication o f HTLV-1, but tax has garnered 
considerable attention due to its ability to activate human genes as well. In addition to its 
ability to bind the cAMP response element (CRE)-containing 21-bp enhancer in the long 
terminal repeat region o f the viral genome, tax binds and activates enhancers containing the 
NF-kB binding site or serum response element (SRE) sites (Ruben et al., 1988). Among 
the human genes known to be activated by tax are several with known involvement in 
proliferative responses, e.g., IL-2 receptor a  chain (CD25), GM-CSF, c-fos, c-egr (Fujii 
et al., 1988; Nagata et al., 1989). Activation of CD25 and c-fos are thought to contribute 
to the first step in the development o f ATL (Maruyama et al., 1987). Through 
interactions with other DNA binding proteins, the gene activating function of tax is 
extremely versatile. Tax interacts with CRE-binding proteins, cAMP response element 
modulator (CREM), NF-kB p50, serum response factor (SRF), and the 36 kDa TRE-2 
binding protein (Yoshida et al., 1995). Tax can also bind and activate an 11-bp 
palindromic sequence (TTTCCGGGAAA) homologous to IFN-y and IL-6 response 
elements (Owen et al., 1997).
There is relatively little known about individual domains within the tax protein. 
Tax mutation studies demonstrate that the N-terminus, and possibly some portion in the 
middle, seems to be important in its ability to bind NF-kB sites and the 21-bp sequence 
in the long terminal repeat region, but which specific residues are involved and how they 
disrupt engagement at docking sites are not yet known (Hirai et al., 1992). Other 
enhancer activators, e.g. Gal4 and herpes virus VP 16, contain a cluster of acidic residues 
which is a critical part o f their activation domains (Ptashne, 1988). Tax contains such a
18
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cluster of acidic residues in its C-terminus and deletion of a 69 bp region encompassing 
the cluster results in loss of DNA-binding capability (Smith et al., 1990).
Since tax does not directly bind DNA, early studies focusing on the nature of tax- 
DNA interactions were directed at finding proteins that could potentially serve as 
adaptors. Thus a series o f new proteins named tax-responsive element binding 
(TAXREB) proteins were discovered by looking for binding to HTLV-1 long terminal 
repeat enhancer sequences. The vast majority of the proteins found belonged to the ATF 
and CREB families. TAXREB 107 was isolated from a Jurkat cDNA library. It is a 288 
amino acid molecule that binds to domain C of the tax-responsive enhancer region, instead 
of domain B as viral tax does (Morita et al., 1993). TAXREB 107 is constitutively 
expressed in a wide range of tissues, and is upregulated beyond basal levels in TP A- 
activated Jurkat T cells. Sequence analysis o f human TAXREB 107 shows very little 
homology with HTLV-1 tax. However, the sequence of TAXREB107 is highly 
homologous to that of ribosomal protein L6, a protein found in the large subunit, p60, of 
eukaryotic systems.
Shortly after the discovery of TAXREB 107, a 227 amino acid protein named 
C140 was described. C140 mRNA levels increase dramatically in malignant, transformed 
rat thyroid FRTL cells compared to nontransformed cells (Ohta et al., 1994). Neoplastic 
thyroid tissue (papillary carcinoma and adenoma) and thyroid tissue from a Grave’s 
Disease patient contain much greater levels of C l 40 mRNA compared with the almost 
negligible levels found in normal tissue. TAXREB 107 and C l40 share over 90% amino 
acid sequence homology. Although no further studies have been done on CKO, it is
19
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
interesting to speculate on its potential functional similarities to tax and in particular, 
TAXREB 107, due to its homology.
In addition to upregulation in neoplastic thyroid tissue, TAXREB 107 is an 
erythropoietin early response gene (Li et al., 1999). A subtractive hybridization strategy 
has been used on Rascher murine erythroleukemia cells to identify TAXREB 107 and 
confirm the observation with Northern blot analysis, That is, a four-fold increase in 
TAXREB 107 mRNA can be detected after 1 hour of erythropoietin treatment. Finally, 
TAXREB 107 may also have a role in regulating cell growth by binding to both high and 
low molecular weight forms of FGF-2, as determined by yeast two-hybrid assays (Shen 
et al., 1998).
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Chapter 2—Establishing the Existence o f an Interaction Between
IC A M -l Cytodomain and TAXREB107
2.1 Goals and Strategy Design
The aim of this work is to study the role o f ICAM-l as an outside-in signaling 
molecule. A number o f proteins have been shown to be activated upon ICAM-l 
stimulation at the cell surface with the majority being downstream components of known 
signaling pathways. However, because the ICAM-l cytodomain does not appear to have 
enzymatic activity, the mechanism by which ICAM-l engagement leads to any 
biochemical activation event is unclear. It is thus likely that critical proteins are recruited 
to the ICAM-l cytodomain, and that these recruited molecules ultimately transduce the 
ICAM-l “outside-in” signals. The few molecules that have been shown to interact 
directly with ICAM-l cytodomain are mostly cytoskeletal subunits or adapter proteins 
for cytoskeletal scaffolds. Although potentially important, it is unlikely that these 
proteins are the molecular triggers for signal transduction. Therefore, there must be other 
ICAM-l cytodomain-interacting proteins. The approach used here began with a general 
screen for molecules capable of interacting with the ICAM-l cytodomain, using a whole 
cell lysate from human umbilical vein endothelial cells, which are known to express 
ICAM-l. Using the GST pulldown technique, potential ICAM-l cytodomain binding 
proteins were identified. After confirming the interactions with alternative techniques, we
21
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
established that these novel components can modulate known effector pathways of 
ICAM-l stimulation.
In the course o f our functional studies, an activating monoclonal antibody, R6.5, 
along with goat anti-mouse secondary antibodies, were generally used to engage ICAM-l 
via “crosslinking”. Besides the obvious advantage of specificity against ICAM-l, the 
primary plus secondary antibody system enables the formation of ICAM-l microclusters 
at the cell surface, which are known to effect activation responses through other surface 
molecules capable of outside-in signaling. In at least one set of experiments, fibrinogen, 
one of the natural ligands, was also used and produced similar effects as that seen with 
antibody stimulation.
2.2 Screening for Interactions with ICAM-l Cytodomain
Previous studies looking for ICAM-l cytodomain interactions screened whole cell 
lysates with ICAM-l cytodomain peptides CNBr-coupled to sepharose beads (Carpen et 
al., 1992; Federici et al., 1996). Although this provides a relatively pure system, a 
potential pitfall is that the CNBr activated beads will bind to any primary amino group in 
the peptide. Since ICAM-l cytodomain contains an abundance of residues that contain 
primary amino groups (3 Arg + 5 Lys out of 31 total residues), this method may 
potentially crosslink only one out o f nine peptides at the intended N-terminus. The 
peptides bound to the beads at any of the intermediate residues may have critical domains 
blocked, thus decreasing the yield o f the pulldown technique.
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In light o f this, a GST-ICAM-I cytodomain fusion protein was generated and 
used to insure the freedom o f the cytodomain to interact without impeding any potential 
functional groups. This system incorporated an ICAM-l cytodomain at the C-terminai 
end of the glutathione-S-transferase, so as to leave the C-terminal end o f the ICAM-l 
cytodomain free as well. The GST-ICAM-1 cytodomain fusion protein was expressed in 
DH5a E. coli bacteria and purified on glutathione beads. The potential disadvantage of 
this system is that a number o f  proteins may be pulled down by virtue o f an interaction 
with GST rather than ICAM-l, thus creating a false positive. However, lysates were 
precleared on GST-coupled beads before incubation with GST-ICAM-1 cytodomain 
beads to deplete such proteins. Care was also taken to run an SDS-PAGE analysis of the 
preclearance with actual pull down samples to make sure that bands of interest were 
visible in the pull down samples only.
A human umbilical vein endothelial cell (HUVEC) lysate was used since previous 
literature had shown that this cell line has ICAM-l signaling capacity (Watson et al., 
1995; Sano et al., 1998). The pulldown proteins were analyzed by SDS-PAGE and silver 
stained according to the Mann protocol (Shevchenko et al., 1996), providing seven total 
bands of interest, ranging from 32-210 kDa. These bands were subjected to in-gel tryptic 
digest and eluted from the gel slices. Matrix assisted laser desorption ionization mass 
spectrometry (MALDI-MS) was performed on the eluted peptide fragments using 100 
finol bradykinin and ACTH clip as internal calibrants. MALDI-MS provides a peak 
profile based on mass spectrometry of all peptides eluted from each sample, which is 
then compared with known peak profiles of other proteins in the database. The primary
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program used was ProFound, which relied on the OWL database. As a secondary backup 
algorithm, PeptideSearch (relies on the EMBL/non-redundant database) was used. A 32 
kDa band was identified by both algorithms as a human thyroid carcinoma cell protein, 
C140. Since C l40 was predicted to only be 19 kDa in size, unlike the 32 kDa band, this 
seemed puzzling at first. However, since this technology is relatively new, only 50% of 
unknown, submitted samples analyzed via MALDI-MS peptide database are identified 
due to the relatively small size o f the database. The fraction o f samples identified 
increases substantially when the protein is from an organism such as E. coli, whose 
genome has been sequenced. Since the probability score using the primary algorithm, 
ProFound, was greater than 90%, it stands to reason that perhaps the real identity of the 
band was that o f a protein with strong similarity to C140. A BLAST search 
subsequently revealed a 32 kDa protein known as TAXREB 107 which has over 90% 
homology with C l 40 and contains a very similar pattern o f tryptic digest sites.
To further confirm the identity o f  the protein, nanospray MS/MS analysis of the 
same sample was performed on a Q-Tof mass spectrometer. Due to some difficulties in 
running the sample through the nanovials, a manual analysis of the match was performed 
and showed a short potential sequence o f  EKY at the N-terminal end o f one of the tryptic 
fragments. Considering that this is a tryptic digest, the residue preceding the first amino 
acid should be either Iys or arg. As predicted, KEKY was found in position 237-240 of 
TAXREB 107’s amino acid sequence, helping to confirm the identity o f the 32 kDa band.
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2.3 Confirming the ICAM-l cytodomain/ TAXREB 107 Interaction
After identifying TAXREB 107 as a likely ICAM-l cytodomain-associated 
protein, the next step was to confirm this molecular interaction by co- 
immunoprecipitation. The initial approach was to design and make a c-myc epitope 
(myc-e) tagged TAXREB 107 since there are no commercially available anti-TAXR£B107 
antibodies. A GFP-labeled ICAM-l cytodomain was also made. The 
pCMV+TAXREB 107 with or without pWAY5+ICAM-l cytodomain construct was 
transfected into Chinese hamster ovary (CHO) cells and allowed to express for 24 hours. 
Figure 1 demonstrates immunoprecipitation of endogenous ICAM-l followed by Western 
blotting for c-myc epitope, using whole cell lysates from CHO cells that had been 
transfected with the pCMV control vector or varying amounts of c-myc-epitope tagged 
TAXREB107. The anti-ICAM-1 polycolonal antibody H-108 recognizes hamster in 
addition to human, mouse and rat ICAM-l. Based upon the c-myc epitope blotting of a 
protein with the appropriate mass (32 kDa), TAXREB 107 is easily identifiable in the 
ICAM-l immunoprecipitates. The efficiency/amount o f the interaction increases with a 
greater amount of TAXREB 107 expressed. Although the transfection efficiency is less 
than in CHO cells (which is why most of these experiments were performed in CHO), 
similar results were obtained when expressing c-myc-epitope tagged TAXREB 107 in the 
ICAM-l-positive human endothelial cell line EA.hy926 (data not shown).
To demonstrate more directly that TAXREB 107 can become associated with the 
ICAM-l cytodomain in cells, c-myc-epitope tagged TAXREB 107 and GFP-ICAM-1
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were co-expressed in CHO cells, and co-immunoprecipitations were performed in the 
opposite direction as in Figure 1. That is, TAXREB107 was immunoprecipitated with an 
anti-c-myc epitope antibody, followed by an anti-GFP antibody. Figure 2 demonstrates 
a TAXREB 107-ICAM-l cytodomain interaction in the co-transfected cells. GFP alone 
did not associate with the transfected TAXREB 107.
In an attempt to duplicate the protein-protein interaction experiments in a non­
transfected system, we generated a rabbit polyclonal anti-TAXREB107 antibody and 
repeated the co-immunoprecipitation experiments, investigating the endogenous molecules 
in the EA.hy926 endothelial cell line. Figure 3 demonstrates that this protein A/G- 
purified polyclonal serum recognizes an endogenous protein that co-migrates with 
overexpressed recombinant TAXREB 107. Figure 4 demonstrates that endogenous 
TAXREB 107 is detectable in ICAM-l immunoprecipitates, and vice versa. In contrast, 
TAXREB 107 was not detectable in PECAM-1 immunoprecipitates. These three 
experiments support the GST pull-down finding of an ICAM-l cytodomain/
TAXREB 107 interaction.
2.4 Yeast Two Hybrid Assay
In an attempt to determine whether the aforementioned molecular association is a 
direct protein-protein interaction, yeast two hybrid assays were performed. Plasmid 
constructs for a  GAL4 binding domain-ICAM-1 cytodomain fusion protein and a GAL4
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Figure 1. Co-immunoprecipitation of recombinant TAXREB 107 with endogenous ICAM- 
1. CHO cells were transfected with the indicated amounts of myc-e/TAXREB107 plasmid 
DNA, after which endogenous ICAM-l was immunoprecipitated. After SDS-PAGE and 
transfer, the blots were probed first with an anti-myc-e antibody (top panel) and reprobed 
with an anti-ICAM-1 antibody (bottom panel). myc-e/TAXREB107 and ICAM-l blotted 
at the expected masses of 32 kDa and 100 kDa, respectively.
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Figure 2. Co-immunoprecipitation of recombinant TAXREB 107 with recombinant ICAM-l CD. 
CHO cells were transfected with myc-e/TAXREB107 plus GFP/ICAM-1 CD or plus GFP alone, 
after which TAXREB 107 was immunoprecipitated with an anti-myc antibody. After SDS-PAGE 
and transfer, the blots were probed with an anti-GFP antibody. GFP/ICAM-1 CD blotted at the 
expected mass of 32 kDa.
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Figure 3. Generation of an anti-TAXREB107 polyclonal Ab. Protein A/G-purified polyclonal 
antibody, obtained from rabbits immunized with GST-TAXREB107, was used in Western blots with 
whole cell lysates prepared from CHO cells transfected with c-myc-tagged TAXREB 107 (left panel). 
Blots were reprobed with anti-c-myc antibody (right panel), identifying the co-migrating band and 
confirming the TAXREB 107 antibody specificity.
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Figure 4. Co-immunoprecipitation of endogenous TAXREB 107 with endogenous ICAM-l, but not 
PECAM-1. (A) Endogenous ICAM-l or PECAM-1 were immunoprecipitated from EA.hy926 cells. 
After SDS-PAGE and transfer, blots were probed first with polyclonal anti-TAXREB107 antibody 
(upper panel), and reprobed with either anti-ICAM-l or -PECAM-1 antibody. (B) Endogenous 
TAXREB 107 was immunoprecipitated from EAhy.926 cells. After SDS-PAGE and transfer, blots 
were probed first with either anti-ICAM-1 or -PECAM-1 antibody and reprobed with polyclonal anti- 
TAXREB107 antibody. ICAM-l, PECAM-1 and TAXREB 107 were blotted at the expected masses of 
100 kDa, 120 kDa, and 32 kDa, respectively.
activation domain-TAXREB107 fusion protein were made by cloning both ICAM-l 
cytodomain and TAXREB 107 C-terminal to the DNA-BD and DNA-AD, respectively. 
These plasmid constructs were then transfected into the Y190 yeast strain for the assay. 
A twofold screen using both HIS3 and lacZ reporters was used to select for positive 
clones. Although several colonies did appear on His* SD plates, subsequent testing of 
these colonies for P-galactosidase activity proved negative, indicating that a direct ICAM- 
1 cytodomain/TAXREB107 interaction did not occur. Parallel experiments for positive 
and negative controls included p53/Large T-antigen and Lamin C/Large T-antigen, 
respectively. These results suggest an indirect interaction between ICAM-l cytodomain 
and TAXREB 107, perhaps involving one or more adaptor proteins.
2.5 Discussion
Given the negative yeast two-hybrid assays, it is possible that the proteins of 
interest are not synthesized normally in yeast, such that their interaction domains may be 
altered. However, an indirect protein-protein interaction is the more likely explanation. 
Numerous examples of indirect interactions exist in current working models of signal 
transduction pathways. Perhaps one o f the best known is that o f the ras signaling 
pathway (Boriack-Sjodin et al., 1998). Transmembrane receptors acting through tyrosine 
kinases activate ras by stimulating the guanine-nucleotide exchange reaction controlled by 
a protein named Son of sevenless (Sos) which acts as a guanine-nucleotide exchange factor
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for ras. Once a ligand binds the transmembrane receptor, the intracellular domain of the 
receptor is tyrosine phosphorylated, often through a dimerization and 
autophosphorylation process. Sos is then recruited from the cytoplasm to the 
phosphorylated receptor with the help o f an adaptor protein named Grb2, which has the 
ability to bind other proteins via its SH2 and SH3 interaction domains. (Rudd, 1999). 
Grb2 binds constitutively to Sos via an SH3 domain and the Grb2/Sos pair is recruited to 
the cell membrane upon tyrosine phosphorylation o f the receptor. At this point, the SH2 
domain of Grb2 is now capable of binding to the receptor. This recruitment brings Sos 
adjacent to ras and promotes the exchange o f GDP for GTP, thereby activating ras.
It is conceivable that an adaptor protein such as Grb2 could directly bind the 
ICAM-l cytodomain and mediate interactions with other proteins. Careful examination 
o f the ICAM-l cytodomain amino acid sequence reveals that amino acids # 519-525 
(approximately the middle portion of the cytodomain) not only fits the basic requirement 
of an SH3 ligand domain (e.g., PXXP motif), but actually resembles a particular class of 
SH3 domain ligands. In particular, the pattern KGXPXXP is found in both ICAM-l 
cytodomain and the amphiphysin (I and II) SH3 ligand consensus sequence (Micheva et 
al., 1997). Amphiphysin is a protein intimately involved in endocytosis. By binding to 
partners such as endophilin, dynamin, and synaptojanin, it helps to mediate the fission of 
endocytic vesicles in nerve terminals. An SH3-mediated binding interaction with the 
ICAM-l cytodomain has not been demonstrated. We performed in vitro binding assays 
using various candidate fusions proteins composed o f GST-SH3 domains from 
Endophilin-1, -2, -3, lyn kinase, fyn kinase, PI3K, and c-src. None o f these SH3 domain
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peptides bound to the ICAM-l cytodomain peptide. Since SH3 domains are known to 
bind with low affinity (Kd = 1-200 fiM) (Nguyen et al., 1998), plasmon resonance was 
employed to increase the sensitivity o f detection. However, this also failed to reveal any 
interactions between the ICAM-l cytodomain and the several candidate SH3 domains 
tested. It remains possible that among the multitude o f known and currently unknown 
SH3 domains, a binding partner for this putative SH3 ligand exists.
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Chapter 3 -- Enhancement o f ICAM -l-m ediated M APK Activity by 
TAXREB107
3.1 Establishing a Cell Line for Examination of TAXREB 107 Effect on ICAM-l-mediated 
MAPK Response
Previous literature has established the existence of MAPK activation responses in 
various cell types after ICAM-l stimulation, including the B cell lymphoma line A20 
(Holland et al., 1997), and primary human umbilical vein cells (HUVEC) (Sano et al., 
1998). Since neither o f these cell lines is easily and highly transfectable, it would be 
convenient for MAPK assays to find other cell lines with higher levels of transfection 
efficiency and that also have low basal levels of resting MAPK activity. In an effort to 
find other cell lines possessing these qualities, a number of cell lines were screened, 
including Chinese hamster ovary carcinoma (CHO), Hela (human cervical epithelial line), 
and COS (monkey kidney line). Of the lines tested, all had relatively high transfection 
efficiencies, but only CHO consistently showed large amounts of TAXREB 107 
expression when transfected and also displayed relatively low basal MAPK activity.
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3.2 Confirmation o f R6.5 Monoclonal Antibody Binding to CHO Cells
As described above, CHO cells are a convenient model to work with due to their 
ease o f transfectability, rapid growth rate, and low MAPK background levels during the 
resting state. However, since there are no commercially available anti-hamster ICAM-l 
antibodies, we evaluated whether R6.5 (BIRR01, Enlimomab), an anti-human-ICAM-1 
murine IgG2a monoclonal antibody, previously shown to have ICAM-l activating 
properties in human cells, could recognize hamster ICAM-l on CHO cells. ICAM-l 
engagement by R6.5 on human neutrophils has been shown to upregulate CD1 lb 
expression, decrease L-selectin expression, and increase oxidative burst. When 
considering the likelihood that R6.5 could recognize hamster ICAM-l, it was encouraging 
that R6.5 recognizes human Ig-like domain #2 (Diamond et al., 1990), which has high 
interspecies homology. When initially testing R6.5 reactivity on CHO cells by flow 
cytometry, all the stainings were negative (data not shown). However, because a signal- 
transducing molecule can be membrane-expressed at a level below the detection threshold 
for FACS, yet remain a competent signaling molecule when engaged by ligand, we utilized 
a fluorescence amplification system. By using protein A-conjugated, 0.4 Jim diameter, 
fluorphore-containing microspheres (fluospheres), hamster ICAM-l (R6.5 reactivity) 
was easily detectable above background (Fig. 5, IRR=isotype-matched anti-LFA-3 and 
anti-CD3 controls) on CHO cells (Fig. 5). Thus, it appeared reasonable to expect an 
activation response to monoclonal antibody R6.5 in CHO cells.
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Figure 5. Flow cytometric analysis of mAb R6.5 recognition of CHO cells using fluospheres. 
CHO cells were incubated with R6.5 followed by staining with protein A-conjugated 
fluospheres. Irrelevant (IRR) controls included isotype-matched murine mAbs TS 2/9 (anti­
human LFA-3) and OKT3 (anti-human CD3). 5000 cytometer-acquired events were analyzed 
per sample.
3.3 TAXREB107 Enhances ICAM-1-mediated ERK 1/2 Activity
To address whether the TAXREB107/ICAM-1 cytodomain interaction has any 
effect on ICAM-1-mediated signaling, a series of MAPK (ERK1 and 2) activation 
experiments were performed in R6.5-stimulated, vector control or TAXREB107- 
transfected CHO cells. Cells were transfected with either a GFP control, GFP-ICAM-1 
cytodomain, or c-myc-epitope tagged TAXREB107 plasmids. After overnight 
transfection, cells were either treated with only goat anti-mouse secondary antibody alone 
(0 min, unstimulated), or treated with R6.5 + goat anti-mouse antibody for 1 or 5 
minutes. Cell lysates were then immunoprecipitated with activation-specific anti- 
phospho-ERK 1/2 antibody and the immunoprecipitates were incubated with an Elk-1 
peptide substrate. Figure 6 demonstrates a phospho-Elk-1 Western blot, in which after 5 
min of ICAM-1 engagement in the setting of only control GFP expression, phospho-Elk- 
1 is detectable (lane 3), i.e. ERK activation occurs. This ICAM-1-mediated activation 
event was greatly augmented in TAXREB107-transfected cells (lane 9). In some 
experimental samples, recombinant ICAM-1 cytodomain was expressed, in an attempt to 
compete for cytodomain interactions, and thus, impart a “dominant negative” effect. In 
this set of experiments, recombinant ICAM-1 cytodomain expression abrogated the 
ICAM-1-mediated ERK activation (fig. 6, lane 6) at 5 min. It is important to note that, at 
the 5 min time point, ERK activation was variably induced by ICAM-1 engagement 
alone. However, the combination of ICAM-1 engagement and TAXREB107 expression 
always activated ERK 1 and 2 (see below). In an attempt to duplicate the above findings
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Figure 6. In vitro ERK assay in R6.5-stimulated cells. CHO cells were transfected overnight 
with plasmids for the indicated proteins, then stimulated for 0, 1 or 5 min using R6.5 a-ICAM- 
1 Ab + GaM Ab. In vitro kinase assays were performed on immunoprecipitated active Erk 1/2 
by adding the Erk 1/2 substrate Elk-1 in the presence ATP. Phospho-Elk-l Western blot is 
shown.
with a natural ICAM-1 ligand (as opposed to antibody-mediated activation), fibrinogen, 
which binds to Ig-like domain-1 o f ICAM-1 (Duperray et al., 1997), was used. Figure 7 
demonstrates that at the 5 min time point, fibrinogen induces ERK 1/2 activation. This 
was also inhibited by expression of recombinant ICAM-1 cytodomain (data not shown). 
The MAPK response to fibrinogen was augmented in TAXREB107-transfected cells. 
These results are absolutely analogous and parallel to those obtained with R6.5, i.e. 
antibody-mediated ICAM-1 clustering, and suggest that the TAXREB107-ICAM-1 
cytodomain interaction is necessary for these potentially important MAPK responses.
3.4 ICAM-1 cytodomain Cotransfection Blocks TAXREB107 Enhancement o f ICAM- 
1-mediated MAPK Response
Inhibition o f the synergistic ICAM-l/TAXREB107-mediated ERK activation 
response with recombinant ICAM-1 cytodomain expression would further support that 
these molecules interact at the level o f the ICAM-1 cytodomain. Figure 8 demonstrates a 
potent, 5 min induction of ERK 1/2 activation with the combination of ICAM-1 
engagement and TAXREB107 expression. This activation is completely inhibited by 
concurrent expression of the ICAM-1 cytodomain (fig. 8, last lane). This finding rules 
out the possibility that antibody-mediated ICAM-1 crosslinking is simply recruiting 
other signaling molecules which, through their cytoplasmic tails, are triggering ERK 
activation. We cannot be certain that other important signaling molecules are not recruited 
but, at the very least, these recombinant cytoplasmic domain expression experiments
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Figure 7. In vitro ERK assay in fibrinogen-stimulated cells. CHO cells were transfected 
overnight with plasmids for the indicated protein and stimulated with fibrinogen, a natural ligand 
for ICAM-1. In vitro ERK assay was performed as described in Figure 6. Phospho-ELK-1 signals 
were densitometrically normalized to IgG heavy chain to account for slight differences in the 
amount of IP Ab added.
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Figure 8. Effect of ICAM-1 CD expression on TAXREB107-enhanced, ICAM-l-stimulated ERK 
activation. CHO cells were transfected overnight with plasmids for the indicated proteins and stimulated 
for the noted time with R6.5 a-ICAM-1 +GaM Ab (except Mock GaM which was stimulated with 
GaM Ab alone), then assayed for in vitro ERK activity as described in Fig. 6. Cells labeled “Mock” 
underwent the same transfection protocol as other samples, but no plasmid was added.
confirm that ICAM-1, itself, is primary to the signaling event, especially given that other 
adhesion-molecule cytodomain overexpressions are not inhibitory (see below).
3.5 ICAM-1-mediated MAPK Activation in the Human Cell Line, HT-29
Although CHO ICAM-1 was clearly recognizable by R6.5 (fig. 4), attempts were 
made to duplicate the above findings in a human, ICAM-1 positive cell line, since R6.5 
was generated against human ICAM-1. HT-29, a human colonic epithelial carcinoma cell 
line expresses R6.5-detectable (by FACS) membrane ICAM-1 without the requirement 
for fluorescence amplification, as in CHO cells. Figure 9 displays an ERK 1/2 activation 
assay performed by Western blot detection of activation-specific, phospho-ERK-1 and 
-2, instead o f the kinase assays displayed in figures 6, 7, and 8. At 5 min of ICAM-1 
engagement (R6.5 stimulation) in TAXREB107-transfected cells, activated ERKs were 
easily detachable. As in CHO cells, this prominent activation was abolished by 
cotransfection with the ICAM-1 cytodomain. Thus, although transfection and MAPK 
experiments could be done more efficiently in CHO cells, identical results were obtained 
in a human cell line.
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Figure 9. ICAM-1-mediated ERK activation in HT-29 human colonic carcinoma cells. HT-29 cells 
were transfected overnight with plasmids for the indicated proteins, then stimulated with R6.5 for 5 
min. Western blotting for activated, phospho-ERK 1/2 (upper panel) was performed, followed by 
reprobing for total ERK 1/2 (lower panel).
3.6 VCAM-1 Cytodomain Cotransfection Does Not Block TAXREB107 Enhancement 
of ICAM-1-mediated MAPK Response
Vascular cell adhesion molecule (VCAM-1) is an endothelial cell adhesion 
molecule and is also a member of the immunoglobulin superfamily, similar to ICAM-l in 
structure. Both possess relatively long extracellular domains containing multiple, in-series 
Ig-like domains, a single transmembrane region, and a very short cytoplasmic tail (Pigott 
et al., 1993). Due to the similarities in overall structure, the VCAM-1 cytodomain was 
used as a negative control for the ICAM-1 cytodomain in inhibition experiments. A 
plasmid construct was made for a GFP-VCAM-1 cytodomain fusion protein with the 
same approach as that used to make the GFP-ICAM-1 cytodomain fusion protein, i.e., 
insertion of VCAM-1 cytodomain sequence downstream of GFP in the pWAY5 vector. 
Figure 10 demonstrates, again, that ICAM-1 engagement (R6.5 stimulation for 10 min) in 
TAXREB107-transfected CHO cells results in a prominent ERK 1/2 activation, as 
detected in phospho-ERK 1/2 Western blotting. This activation was completed abrogated 
by cotransfection o f the ICAM-1 cytodomain but not the VCAM-1 cytodomain, 
confirming specificity o f the inhibitory effect. This further supports the importance of 
ICAM-1’s cytoplasmic domain involvement in the noted signaling responses.
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Figure 10. Effect of VCAM-1 CD on TAXREB107-enhanced ICAM-1-mediated ERK activation. 
CHO cells were transfected overnight with the plasmids for the indicated proteins and stimulated with 
R6.5 plus GaM Ab. Western blotting for activated, phospho-ERK 1/2 was performed (upper panel), 
followed by reprobing for total ERK 1/2 (lower panel).
3.7 ICAM-1-deficient Cell Line 2FTGH Lacks an R6.5-induced MAPK Response
As another important control for the ICAM-1 specificity of the R6.5 plus 
TAXREB107-induced responses, a series o f  experiments were performed in an ICAM-1 - 
negative variant o f the human fibroscaroma line 2FTGH. Both conventional FACS 
staining and use o f fluosphere amplification yielded negative results with this line (data 
not shown). Figure 11 demonstrates that, despite a competent ERK activation response 
to phorbol 12-myristyl 13-acetate (PMA), neither R6.5 stimulation alone, nor R6.5 
stimulation in TAXREB107-transfected cells resulted in 2FTGH ERK activation. 
TAXREB107 transfectants expressed levels o f myc-epitope-TAXREB107 similar to that 
achieved in the CHO and HT-29 experiments, as detected by myc-epitope Western 
blotting (not shown).
3.8 Discussion
These experiments reproducibly demonstrate that TAXREB107 overexpression 
is capable of enhancing the MAPK activation response resulting specifically from 
ICAM-1 engagement, and that the ICAM-1 cytodomain is involved in this potentiating 
effect. Many in vitro targets of MAP kinases have been described. At this time, we do 
not know which major classes of downstream effectors are activated by ICAM-1 
stimulation. Examples o f MAPK targets include nuclear transcription factors, metabolic 
enzymes, cytoskeletal proteins, and other signaling proteins (Lewis et al., 1998). Of
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Figure 11. Effect of anti-ICAM-1 R6.5 stimulation in an ICAM-1-deficient cell line. 2FTGH 
fibrosarcoma cells were transfected overnight with plasmids for the proteins indicated, then 
treated for 5 min with R6.5 (or antibody control) plus GaM Ab. Alternatively, cells were mock 
transfected (no DNA) and activated with PMA (1.62 nM) for 5 min. Western blot for activated 
phospho-ERK 1/2 was performed (upper panel), followed by reprobing for total ERK 1/2 (lower 
panel).
note, a family o f protein kinases called MAPKAP kinases (MAPK-activated protein 
kinases) was among the first group of proteins shown to be activated by ERKs. 
MAPKAPs activate numerous transcription factors including cAMP response element- 
binding protein (CREB), CREB-binding protein (CBP), c-fos, Nur77, and serum response 
factor (SRF) (Lewis et al., 1998). There is a remarkable similarity between this list of 
transcriptional activators and those activated by viral tax. As mentioned in the 
introduction, viral tax is capable of activating CREB, c-fos, and SRF. It is tempting to 
speculate that, despite the lack o f significant sequence homology between viral tax and 
human TAXREB107, they may serve similar functional roles, either through involvement 
in enzymatic cascades, and/or direct gene activation (see below). One of the major 
transcription factors activated by viral tax is NF-kB, but this apparently is not activated 
by the ERK signaling pathway (Bocco et al., 1996). We have begun to investigate 
whether other MAPK family members are activated by ICAM-1 engagement, with or 
without TAXREB107 interaction. Preliminary JNK/SAPK activation experiments in 
ICAM-1 stimulated CHO cells have been negative. The p38 pathway was shown to be 
activated by ICAM-1 crosslinking in rat astrocytes (Lee et al., 2000).
ERK activation has also been shown to mediate cytoskeletal events. This may be 
an important, ICAM-1-mediated alternative mechanism to regulate cytoskeletal 
rearrangement. Addition of active ERK to cell-free extracts of Xenopus oocytes results in 
microtubule polymerization (Gotoh et al., 1991). In addition, neuronal cell function can 
be altered by activated ERKs, in that ERK phosphorylates microtubule-associated 
proteins 1/2, Tau, and synapsin I (an actin-binding protein involved in cross-linking
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synaptic vesicles with the cytoskeleton (Lewis et al., 1998). To date, no ERK-mediated 
cytoskeletal studies have been performed in endothelial cells, which have generally 
focused on rho-activated pathways (Adamson et al., 1999; Hirase et al., 2000).
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Chapter 4 -- TAXREB107 Translocates to the Nucleus After ICAM-1 
Stim ulation
4.1 Cellular Localization o f TAXREB107
There are recent reports of ICAM-1 modulation o f gene expression, including 
activation o f the ICAM-1 gene itself. Although we have described above how 
TAXREB107 and ICAM-1 interact to induce a rapid signaling event (ERK activation), it 
remains possible that, even in this ICAM-1-stimulated context, TAXREB107 has an 
additional role, specifically in gene expression. Viral tax can bind to NF-tcB DNA 
elements (Ruben et al., 1988). Since TAXREB107 can bind tax-responsive elements, 
perhaps if  TAXERB107 is located in the nucleus after ICAM-1 engagement, it could be 
involved in NF-KB-dependent gene activation, e.g., in the ICAM-1 gene itself.
TAXREB 107 has only recently been cloned and its subcellular localization has 
not been defined. In order to evaluate TAXREB 107’s subcellular localization, with and 
without ICAM-1 stimulation, c-myc-epitope tagged TAXREB 107-transfected CHO cells 
were R6.5 or isotype-matched control antibody + Goat anti-mouse secondary antibody 
treated for 30 min, fixed, permeabilized and stained with a rhodamine-conjugated anti-c-
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myc-epitope monoclonal antibody. As negative controls, rhodamine-conjugated irrelevant 
antibody staining in TAXREB 107-transfected cells, and vector control (without 
TAXREB 107)-transfected cells both yield negligible background staining (Figure 12). 
Figure 13 demonstrates a diffuse, cytoplasmic TAXREB 107 distribution in 
TAXREB 107-transfected, non ICAM-1-stimulated cells. In  addition, there may be a 
small amount o f punctate, intranuclear (possibly nucleolar) staining. Upon stimulation 
for 30 minutes, a  majority o f TAXREB107 translocates to the nucleus (Figure 14). These 
data demonstrate, for the first time, the subcellular localization o f TAXREB 107, and that 
it rapidly translocates to the nucleus upon cell activation. This also raises the possibility 
that one of the consequences o f ICAM-1 engagement could be to promote nuclear 
localization o f a protein that, although not defined as such, may be an important 
transcription factor.
4.2 TAXREB 107 Sequence Analysis
Analysis o f TAXREB 107 sequence reveals the presence o f a bipartite nuclear 
localization signal (NLS) in the N-terminal portion of the molecule at positions 14-31 and 
70-87. However, control of nuclear import is not dependent purely on the presence of an 
NLS. Rates o f nuclear import have been shown to be dependent on two other important 
factors: nuclear membrane-associated proteins and phosphorylation o f sequences within 
or flanking the NLS. A classic example is the NLS of SV40 Large T antigen (Dingwall et 
al., 1991). When this NLS (aa 126-132) and the 15 bps of sequence upstream (aa 111-
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Figure 12. Negative control immunofluorescence staining for TAXREB 107 localization studies. 
CHO cells were transfected overnight with myc-epitope alone, fixed, permeabilized, and stained 
with a rhodamine-conjugated a-myc-e Ab. 400X magnification.
Figure 13. TAXREB 107 Cellular Localization In Unstimulated CHO cells. CHO cells were 
transfected overnight with TAXREB 107/myc-e, fixed, permeabilized, and stained with a rhodamine- 
conjugated a-c-myc mAb. 400X magnification.
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Figure 14. TAXREB 107 Cellular Localization In ICAM-1 Stimulated CHO cells. CHO cells were 
transfected overnight with TAXREB 107/myc-e, stimulated with R6.5 anti-ICAM-1 mAb for 30 minutes, 
fixed, permeabilized, and stained with a rhodamine-conjugated a-c-myc mAb. 400X magnification.
125) are fused with (3-galactosidase, nuclear import o f the fusion protein occurs. The 
fifteen base pair upstream sequence contains several Ser/Thr phosphorylation sites that 
are substrates for casein kinase H. When these sites are mutated, fusion protein uptake is 
slowed dramatically. TAXREB 107 localization could be under control of the same 
enzymatic events. Within the downstream element o f the bipartite nuclear localization 
signal (aa 78-81), there is a casein kinase II phosphorylation site. Also, there is a protein 
kinase C phosphorylation site directly upstream (aa 64-66) of this same bipartite NLS. 
Either or both o f these phosphorylation sites could play a role in the nuclear import o f 
TAXREB 107 after ICAM-1 stimulation. It is also possible that some other, non-kinase 
activation event is required to conformationally alter TAXREB 107 from a three- 
dimensional configuration that conceals its NLS, to one in which it is exposed. It is 
tempting to speculate that TAXREB 107 may be sequestered in the cytoplasm by its 
interaction with the ICAM-1 cytodomain, and translocates upon release or 
conformational change induced by stimulation.
In an attempt to visualize the translocation of TAXREB 107 from the cytoplasm 
to the nucleus in real time and without the requirement for fixation and antibody staining, 
a GFP-TAXREB107 fusion construct was made and transfected into CHO cells. The 
goal was to track TAXREB 107 translocation by recording images of live cells 
immediately after ICAM-1 engagement. However, when the fusion protein was 
expressed, it was invariably found in the nucleus, even prior to R6.5 stimulation. 
Addition of R6.5 caused no change in the nuclear localization of GFP-TAXREB107.
55
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Why the fusion protein constitutively localizes to the nucleus is unclear at this time, 
although problems with cellular localization have been observed with other GFP fusion 
proteins (Cubitt et al., 1995; Gerdes et al., 1996). When CHO cells were transfected with 
GFP alone, the majority o f the GFP remained cytosolic, with a small amount residing in 
the nucleus. It is possible that GFP causes a conformational change in TAXREB 107, 
especially since its NLS is in the N-terminal portion o f the molecule. Attachment o f GFP 
to the N-terminus of TAXREB 107 may have resulted in a conformational exposure o f the 
NLS, and enhanced nuclear import.
4.3 Discussion
It is intriguing that a DNA-binding molecule such as TAXREB 107 affects the 
activation of a MAPK pathway. Other known examples o f DNA-binding proteins 
interacting with surface molecules include the STAT (Signal Transducers and Activators 
of Transcription) family of proteins. The STATs work in a novel way to transduce 
signals from cytokine receptors by going directly from their membrane-associated location 
to DNA, without any intermediate kinase cascade components as seen with many other 
outside-in signaling pathways. A basic model o f this pathway is as follows (Leonard et 
al., 1998): cytokine receptors such as IL-2 and IL-15 receptors interact constitutively 
with Janus kinases (Jaks). The presence of the appropriate cytokine ligands activates the 
Jaks which phosphorylate tyrosine residues on the receptor. The STATs, which reside 
in the cytosol in their latent form, possess SH2 domains (phospho-tyrosine recognizing
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domains) that are able to bind the phosphorylated cytokine receptor, to which they are 
recruited. Jaks then phosphorylate the STATs which form homo or heterodimers, 
translocate to the nucleus and bind specific DNA target sequences.
It is interesting to speculate on the mode of action o f TAXREB 107 after ICAM-l 
stimulation, for it seems that there are both similarities to and differences from the 
mechanism by which STAT molecules transduce signals. One major difference is that 
TAXREB 107 can enhance the phosphorylation o f ERK 1/2, suggesting that 
TAXREB 107 can interact with other cytosolic molecules after initial ICAM-1 
stimulation, rather than go directly to the nucleus as STATs do to activate specific genes. 
On the other hand, the observation that a DNA-binding protein such as TAXREB 107 
may bind the ICAM-1 cytodomain in an inactive state implies that it may act like a 
STAT. Both begin their signal transducing pathway at the cell membrane and end in the 
nucleus, likely at a specific promoter site, except that TAXREB 107 may interact with the 
MAPK pathway at some intermediate point. It is not known whether TAXREB 107 
forms dimers in order to translocate to the nucleus.
If TAXREB 107 does indeed translocate to the nucleus and activate gene 
expression, it would be interesting to see what these targets are. TAXREB 107 was 
discovered using a screen for proteins capable of binding to a specific stretch of DNA 
previously shown to act as a binding site for the HTLV-1 transactivator tax. It stands to 
reason that perhaps genes that could be upregulated by viral tax, may also be targets for 
TAXREB 107. One o f the earliest known tax-regulated genes is the IL-2 receptor a - 
subunit (CD25), a protein critically involved in the proliferative T cell response (Ruben et
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al., 1988). A short segment within the CD25 promoter, GGGGAATCTCCC, interacts 
with viral tax. We tested the possibility that ICAM-1 stimulation could upregulate CD25 
expression in Jurkat T cells. CD25 transcriptional activation was first tested using both 
RT-PCR and a CD25 promoter/luciferase reporter system. Although there were positive 
experiments, neither experimental system produced sufficiently consistent results that 
allowed us to make a conclusion. FACS analysis using anti-CD25 antibodies was also 
performed with similar inconsistent results. In light of the MAPK enhancement activity 
seen in cells stimulated with ICAM-1 antibodies after transfecting with TAXREB 107, we 
measured CD25 expression after transfection with TAXREB 107. Unlike the MAPK 
effect, TAXREB 107 expression did not significantly change CD25 levels in ICAM-1 
stimulated cells.
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Chapter 5 — Conclusion and Future Studies
5.1 Summary
In the work described here, the recently discovered molecule, TAXREB 107, was 
determined to interact with the ICAM-1 cytoplasmic domain. As one of the few 
instances where a non-cytoskeletal associated protein was found to bind the ICAM-1 
cytodomain, these studies describe a novel mechanism involving the proximal ICAM-1 
signaling pathway. Initially discovered by the GST pulldown technique followed by 
MALDI spectrometry, the ICAM-1 cytodomain/TAXREB107 interaction was then 
confirmed by co-immunoprecipitation studies. An attempt to establish whether the 
interaction is direct, using the yeast two-hybrid assay, suggested that it may not be. 
However, lack of reporter expression in these studies does not exclude the possibility o f 
known pitfalls in the yeast two-hybrid system, including those involving nuclear import. 
Therefore, it may very well be that the ICAM-1 cytodomain/TAXREB107 interaction is 
direct, but was not detectable by the yeast two-hybrid assay.
We have not defined the exact role of TAXREB 107 in ICAM-1-mediated 
signaling. It may well be one of several (or many) proteins that can directly or indirectly 
interact with the short cytodomain of this important cell adhesion molecule. In our 
studies, we examined TAXREB 107’s effect on a known downstream ICAM-1-mediated 
signaling event, ERK activation. TAXREB 107 overexpression in CHO cells was able to
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significantly enhance the ICAM-1-mediated ERK activation response. It is important to 
note that this induction occurred only upon ICAM-1 engagement, and not in non­
activated cells, even when TAXREB 107 was overexpressed. In an effort to demonstrate 
the ICAM-1 specificity o f this event, recombinant GFP-ICAM-1 cytodomain fusion 
protein was co-expressed with TAXREB 107 in CHO cells, resulting in complete 
inhibition o f the MAPK activation after ICAM-1 engagement. A control GFP-VCAM-1 
cytodomain fusion protein was unable to block the ICAM-1-mediated MAPK response, 
demonstrating ICAM-1 specificity.
Indeed, the cellular function o f TAXREB 107 is currently unknown, although there 
is evidence that it can translocate to the nucleus due to the presence of a bipartite nuclear 
localization signal. Once inside the nucleus, it can potentially bind specific DNA 
sequences as shown by its ability to interact with the long terminal repeat region of the 
HTLV-1 genome. For the first time, we now demonstrate that TAXREB107 has a 
predominantly cytoplasmic distribution in non-activated cells, but rapidly translocates to 
the nucleus upon ICAM-1 engagement. Mechanisms governing this translocation require 
additional study.
5.2 Model o f ICAM-1 Signaling Through TAXREB 107
Undoubtedly, there remains much work to be done to sort out the molecular 
details of the ICAM-1/TAXREB 107 interaction and its potential role in a novel signaling 
pathway. Based on the information presented in this work, we can, however, provide a
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hypothetical model describing the role of TAXREB107 in the proximal portion of the 
ICAM-1 signaling pathway (Figure 15). In this model, the ICAM-1 cytodomain binds to 
TAXREB107 either directly or via adaptor proteins in the unstimulated state. This may 
be one o f the cytosolic anchors by which TAXREB107 is localized to the cytoplasm 
rather than the nucleus, despite its possession of a bipartite nuclear localization signal. 
The interaction with the ICAM-1 cytodomain (and other cytosolic proteins) may 
promote a conformation that either conceals its NLS, or dramatically slows the rate of its 
nuclear import. When ICAM-1 is engaged at the cell surface, TAXREB107 detaches 
from ICAM-1. Whether it leaves with one or more adaptor proteins or alone has yet to 
be determined. In either case, it now has the ability to activate ERK 1/2, probably 
indirectly, since sequence analysis o f TAXREB107 does not reveal the presence of any 
known kinase domains. Another possibility would be that, upon ICAM-1 dissociation, 
the ICAM-1 cytodomain can then interact with other cytosolic proteins, creating a 
signaling scaffold leading to ERK activation. Although possible, this is less likely because 
the profound potentiation of ERK activation by TAXREB107 overexpression cannot be 
explained in this fashion. Finally, TAXREB107 translocates across the nuclear 
membrane, presumably to activate specific genes whose promoter regions resemble the 
TAX responsive enhancer found in the HTLV-1 long terminal repeat region. Potential 
candidate genes for TAXREB107-mediated activation have yet to be determined.
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Figure 15. Theoretical model of an ICAM-1-mediated signaling pathway showing either a direct or 
indirect ICAM-1 CD/TAXREB107 interaction, leading to Erk 1/2 activation and TAXREB 107 
translocation to the nucleus.
5.3 Future Studies
Future studies will include pinpointing the critical sequences in TAXREB 107 and 
ICAM-1 cytodomain that mediate their interaction, screening for adaptor molecules that 
promote the indirect TAXREB 107/ ICAM-1 cytodomain association, screening for 
TAXREB 107-modulated genes, and defining further cellular/functional effects of ICAM-1 
engagement, especially those that require the noted TAXREB 107 interaction.
Mutagenesis studies will be performed to pinpoint the sequences/domains within 
TAXREB 107 and the ICAM-1 cytodomain that are required for the molecular 
interaction. TAXREB 107 has a stretch of charged residues that may be important for 
ionic interactions with the basic region of the ICAM-1 cytodomain. One may either start 
with mutagenizing these regions or systematically proceed with deletions of 
TAXREB 107 portions in series. With regard to the ICAM-1 cytodomain, it contains an 
SH3 consensus binding sequence which includes the classical PXXP motif preceded by a 
basic residue at the —2 position. Although a number of SH3 domains were found to be 
non-interactive with this region, these were but a few of hundreds o f possible SH3 
domains. It is possible that an SH3-containing adaptor protein requires this region to 
mediate the ICAM-1/TAXREB 107 binding interaction. The short length of the ICAM-1 
cytodomain is an advantage. Since only 30 residues are involved, it is entirely possible to 
perform an alanine scanning experiment on the entire ICAM-1 cytodomain amino acid 
sequence. The recombinant mutants will be screened in ICAM-1 co-immunoprecipitation 
and ERK activation assays.
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Defining the associated/adaptor proteins that mediate the indirect interaction 
between TAXREB 107 and ICAM-1 cytodomain could provide insight into their 
dissociation after ICAM-1 surface engagement Also, because TAXREB 107 does not 
have any known kinase domains, it may interact with another kinase that is capable of 
phosphorylating ERK 1/2, perhaps Raf or MEK. Thus, future experiments will include 
screening for other TAXREB 107-interacting proteins, initially by the yeast two-hybrid 
approach. One potential difficulty, however, besides inherent to the technique, is that 
some interactions may take place only very transiently and thus may not be easily 
detectable. In order to define these interactions, it may be necessary to perform time 
series co-immunoprecipitation studies, looking for the transient associations occurring 
after ICAM-1 stimulation.
Future plans also include to search for TAXREB 107-modulated genes. As 
described above, TAXREB 107 was first discovered as a  DNA-binding protein that 
recognizes domain C o f the HTLV-1 long terminal repeat. Planned approaches include 
differential analysis with gene chip array and utilizing the ever-expanding genome 
database to systematically search for potential TAXREB 107-activatable genes based on 
identifying sequences similar to its known binding site.
Finally, plans also include to examine the effects o f TAXREB 107 expression on a 
variety o f described ICAM-1-stimulated cellular responses, both ERK-dependent and 
—independent. These include endothelial cell proliferation, junctional complex formation, 
alterations in permeability and regulation o f the actin cytoskeleton.
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Chapter 6 M aterials and Methods
Cell lines
The Chinese hamster ovarian cancer cell line (CHO) was obtained from the 
American Type Culture collection (Rockville, MD). CHO cells were cultured in 
FI 2/Ham. HT-29 human colonic carcinoma cells were kindly provided by Dr. David 
Rimm and cultured in DMEM. Fibrosarcoma cell line 2FTGH, obtained from the 
Cleveland Clinic Foundation, was cultured in high-glucose DMEM. All culture media 
were supplemented with 10% FBS, 1 mM glutamine, 100 U/ml penicillin, 100 jig/ml 
streptomycin sulfate (all from Life Technologies, Gaithersburg, MD).
Antibodies and Chemicals
Mouse anti-human ICAM-1 monoclonal antibody (clone R6.5) was protein A 
purified from ascites generated in our laboratory. Goat anti-mouse IgG (H+L) was 
purchased from Zymed Laboratories, Inc. (San Francisco, CA). Rabbit anti-human 
ICAM-1 polyclonal antibody (clone H-108) and mouse anti-c-myc epitope monoclonal 
antibody (clone 9E10) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-TAXREB107 antibody was produced by injecting rabbits with full-length 
TAXREB 107 protein (made first as a GST fusion protein) and protein A purifying the 
serum. Anti-ACTIVE MAPK polyclonal antibody (a-phospho-Erk 1/2) was purchased 
from Promega (Madison, WI). Anti-total Erk 1/2 polyclonal antibody was purchased 
from New England Biolabs (Beverly, MA). Anti-GFP monoclonal antibodies were
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obtained from. Clontech (Palo Alto, CA). Rhodamine-conjugated anti-c-myc monoclonal 
antibody was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Protein A- 
conjugated Fluospheres were purchased from Molecular Probes (Eugene, OR). Secondary 
goat anti-mouse antibodies were purchased from Jackson ImmunoResearch Laboratories, 
Inc. (West Grove, PA). Fibrinogen was purchased from Sigma (St. Louis, MO).
Anti-TAXREB107 Antibody
Polyclonal anti-TAXREB107 antibody was generated by im m u n iz in g  rabbits with 
a purified GST-TAXREB107 fusion protein (prepared from lysed DH10B cells) coupled 
to Freund’s adjuvant. This polyclonal antibody reacted specifically against a c-myc- 
tagged full length TAXREB 107 produced in CHO cells, but not against the c-myc tag 
itself. Briefly, CHO cells transfected with a plasmid containing c-myc tagged 
TAXREB 107 were lysed in sample buffer and the whole cell lysate was analyzed by 
Western blotting with 10% SDS-PAGE. Total immunoglobulin was purified from rabbit 
serum with Protein A agarose beads and used to probe the blot in a 1:1000 dilution in 5% 
nonfat milk TBST. After several washes in TBST, a secondary goat-anti-rabbit-HRP 
antibody from Jackson Immunologicals was used at 1:10,000 in 5% nonfat milk TBST.
GST Pulldown
GST-ICAM-1 cytodomain fusion protein was bound to glutathione-conjugated 
agarose beads (Sigma, St. Louis, MO). GST alone was conjugated to glutathione beads as 
a negative control. A human umbilical vein endothelial cell lysate was run over the bead
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columns and washed 3X with lysis buffer. Beads were then boiled in a reducing buffer, 
run on 10% SDS-PAGE, and silver stained. Protein bands present in the GST+ICAM-1 
cytodomain sample, but not in the negative control, were excised, tryptic-digested and 
sent out for mass spectrometry analysis to determine the protein identity.
MALDI Spectrometry
Bands isolated by GST pulldown were subjected to in-gel tryptic digests and sent 
for matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) at Yale 
University’s William Keck facility for identification by match-up of the peak profile 
against known peak profiles using two different search algorithms on two separate 
databases (OWL and EMBL).
Co-immunoprecipitation
Depending on whether endogenous or recombinant proteins were being examined, 
lysates were made from either transfected CHO cells or non-transfected EA.hy926 cells. 
Lysates were obtained from transfectants 16 hr after transfection. Lysis buffer consisted 
of 20 mM Tris (pH 7.5), 150 mMNaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X-100,
2.5 mM sodium pyrophosphate, 1 mM sodium vanadate, 1 ug/ml leupeptin, 1 tablet 
Boehringer-Mannheim protease inhibitor tablet per 10 mL. Immunoprecipitation was 
performed with 2 fig antibody/400 p.g protein at 4°C O/N with gentle rocking, plus 50 pi 
Protein A/G sepharose slurry (Santa Cruz Technologies, Santa Cruz, CA) for 1 hr at 4°C. 
Immunoprecipitates were then washed 3X with 1 mL lysis buffer and 50 pi 8X sample
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buffer was added, run on a 10% SDS- PAGE, followed by Western blotting (see Western 
blotting, below).
ERK Assay
ERK activation assays were performed using two methods, in vitro kinase assays 
and direct Western blotting for activated ERKS. For in vitro kinase assays, cells were 
serum starved overnight and then treated with either R6.5 monoclonal antibody or 
fibrinogen for the required amount of time, washed once with ice-cold PBS, and lysed in 
20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X-100,
2.5 mM sodium pyrophosphate, 1 mM sodium vanadate, 1 gg/ml leupeptin, 1 tablet 
Boehringer-Mannheim protease inhibitor tablet per 10 mL. Lysates were sonicated 4 x 5  
sec each on ice, followed by 10 min centrifugation at 12000 x g. 200 gg o f cell lysate was 
taken from each sample and added to 15 gl of immobilized phospho-Erk 1/2 monoclonal 
antibody (NEB). Since activated p44/42 MAPK is phosphorylated at Thr202 and 
Tyr204, this antibody was designed to recognize the pTEpY sequence, thus binding to 
only the activated MAPK molecules. Samples were incubated at 4°C for 4 hrs with 
gentle rocking, then microcentrifuged for 30 sec at 4°C, washed 2x with 0.5 mL ice-cold 
lysis buffer, followed by 2x 0.5 mL ice-cold kinase buffer (25 mM Tris (pH7.5), 5 mM (3- 
glycerolphosphate, 2 mM DTT, 0.1 mM sodium vanadate, 10 mM MgC^). Washed 
beads were suspended in 50 gl kinase buffer supplemented with 200 gM ATP and 2 gg 
Elk-1 fusion protein, incubated 30 min at 30°C, and terminated with 25 gl 8X sample 
buffer. Samples were then boiled for 5 min and analyzed by 10% SDS-PAGE. Western
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blotting was performed as described below, with an a-phospho-Eik-1 specific monoclonal 
antibody.
For direct phospho-ERK assays, CHO cells transfected with the indicated 
constructs were lysed in 8X sample buffer, scraped into Eppendorf tubes and boiled 5 
min. 20 pi sample was then run on 10% SDS-PAGE, transferred and Western blotted 
with a-phospho-ERK 1/2 antibody (1:3000 in 5% non-fat milk TBST O/N 4°C) plus 
goat-anti-rabbit-HRP secondary antibody (1:10,000 in 5% non-fat milk TBST 1 hr RT). 
This antibody recognizes the identical pTEpY sequence described above. The blots were 
then stripped and reprobed for total ERK 1/2.
Transfections
Cells were transfected using Lipofectamine PLUS (Life Technologies, 
Gaithersburg, MD). Briefly, for a  60 mm culture dish, approximately 2 pg plasmid DNA 
were incubated with 8 pi PLUS reagent for 20 minutes RT, then mixed with a diluted 
sample of Lipofectamine (12 pi Lipofectamine in 2 ml serum free media), and incubated at 
RT for another 20 minutes. The adherent cell monolayer was washed once with serum 
free medium and then incubated in the transfection mixture for 3.5 hrs. 37°C, 5% C 02. 
The transfection media was then aspirated and fresh serum free media was added to the 
cells and placed at 37X , 5% C 02 O/N.
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Plasmid Constructs
A fusion protein containing an N-terminal Glutathione-S-Transferase and C- 
terminal ICAM-1 cytodomain (aa 502-532) was constructed in the pGEX-2T vector 
(Pharmacia Biotech, Piscataway, NJ) by first generating ICAM-1 cytodomain insert by 
PCR with primers followed by digestion and insertion into the BamHI/EcoRI sites o f 
pGEX-2T.
Upper primer: 5 ’ -CTGGATCCATGGCGGGTGAAAAAGTTGAGAAG-3 ’
Lower primer: 5 ’ -CCGGAATTCTTAGAACACCAATTTGTGAGG-3 ’
c-myc tagged vectors were produced using the pCMV-Tag3 system (Stratagene, La Jolla, 
CA). TAXREB 107 insert was generated by PCR,
upper primer: 5 ’ -GGAATT CAT GGCGGGT GAAAAAGTT GAGAAG-3 ’ 
lower primer: 5 ’ -CCGCT CGAGTTAGAAC ACC AATTT GT GAGG-3 ’
digested with EcoRI and Xhol, then inserted into the pCMV-T3 vector. N-terminal GFP 
tagged vectors were produced using the pWAY5 vector (kind gift from Dr. Tom Hughes). 
For the GFP-ICAM-1 cytodomain construct, ICAM-1 cytodomain was again generated 
by PCR.
upper primer: 5’-CTCAGCAAGCTTCTCTATAACCGCCAG-3 ’
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lower primer: 5’-CCGCTCGAGTCAGGGAGGCGTGGCTTG-3’
PCR product ends were polished with mung bean nuclease and subjected to EcoRI 
digestion, then inserted into pWAY5. The GFP-VCAM-1 cytodomain insert was made 
as separate single stranded 5’-phosphorylated DNA oligomers,
upper strand: 5 ’ - AG AAAAGCC AAC AT G AAGGGGT CAT AT AGT CTT GT AG 
AAGC AC AGAAAT C AAAAGT GT AGC-3 ’ 
lower strand: 5 ’ -T CGAGCTAC ACTTT G ATTTCTGT GCTT CT AC AAG ACT A 
T AT G ACCCCTT CAT GTT GGCTTTT CT-3 ’
which were then annealed and ligated into Smal/Xhol predigested pWAY5 vector.
Immunofluorescence Staining
Cells grown on coverslips were incubated in methanol at -20°C x 5 min., washed 
IX with CMF-PBS, then blocked with 1% BSA CMF-PBS +  0.1% NaN3 x 20 min at 
RT. After another CMF-PBS wash, cells were probed with primary, fluorochrome- 
conjugated antibody at the indicated concentrations, then washed 3X with CMF-PBS at 
RT x 5 min each. Cover slip stainings were then mounted on glass slides for 
visualization and photography on a Microphot Immunofluorescence microscope (Nikon, 
Japan).
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Flow Cytometry
Cells were harvested by trypsinization (Sigma, S t  Louis, MO) and staining with 
primary then fluorophore-conjugated secondary monoclonal antibodies in a 1% BSA 
CMF-PBS solution containing 0.1% sodium azide. Approximately 5000 cells were 
analyzed per sample on a FACSort machine (Becton Dickinson & Co., San Jose, CA), 
using the Cellquest program. Isotype-matched controls were used for all experimental 
samples.
Fluosphere Detection of R6.5 binding to CHO Cells
Briefly, protein A-conjugated 0.4 pm diameter microspheres (fluospheres) were 
washed twice with 50 mM sodium borate pH 8.2, added to R6.5 (130 pg/mL) for 45 
minutes RT, then washed again in 1% BSA D-PBS. After resuspending the cells in 
blocking solution, the R6.5 + fluospheres were added to 1 X 106 CHO cells in suspension 
for 30 minutes at 4°C. A final wash with 1% BSA D-PBS, followed by resuspension in
0.5 mL D-PBS, prepared the cells for FACS analysis. Since the emission spectra o f the 
fluorophore in the beads has peak intensity at approximately 505-515 am, a standard 
FITC channel was used to detect signals in the FACS analysis.
Western Blot Analysis
Cell lysates were boiled for 10 min in sample buffer (0.35 M Tris-Cl, 10.28% 
SDS, 30% glycerol, 10% DTT, 0.012% bromophenol blue) then loaded onto 10% SDS- 
polyacrylamide gels. Total protein loaded onto each lane was identical, as determined by
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Bradford Assay (Bio-Rad, Hercules, CA). Gels were run in running buffer (0.124 M Tris 
base, 0.96 M glycine, 17.3 mM SDS) at 100 V while the dye remained in the stacking gel, 
and 200 V for the remainder o f the run. Transfer onto 0.45 pm pore size nitrocellulose 
was performed in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) 
at 4°C x 1 hr with 100 V using a Bio-Rad transfer apparatus. Samples were then blocked 
x 1 hr RT with 5% milk TBST (50 mM Tris-HCl, 750 mM NaCl, 0.25% Tween) and 
incubated with primary antibody overnight at 4°C on a rocker. Blots were subsequently 
washed 3X with TBST x 10 min each, incubated with secondary antibody x 1 hr at RT in 
5% milk TBST and washed again 3X for 10 min with TBST. Finally, blots were reacted 
with chemiluminescence solution (NEN, Boston, MA) for 1 min at RT, followed by 
exposure to film (Amersham, Buckinghamshire, England).
Purification of ICAM-1 Cytodomain Peptides on SCX Columns
SCX columns (Millipore Corp., Bedford, MA) were washed in methanol and 
distilled water before loading the ICAM-1 cytodomain peptides 2392 and 2393.
Columns were spun 1200 x g 1 min, washed with 0.5 ml 10 mM HC1. Elution was 
performed with 50 pi 1.4 N NH40H/MeOH and spinning 12000 x g. Samples were then 
dessicated under vacuum for 15 min and resuspended in HBS buffer (Biacore Inc., 
Piscataway, NJ).
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